BMY - Beam Therapeutics: Recent Selling Pressure Leaves Behind A CRISPR Buying Opportunity

• BEAM's novel CRISPR technology gives it a niche in a crowded and volatile market alongside other CRISPR companies trading at high valuations.
• While the 'standard' CRISPR-cas9 approach cuts double-stranded DNA and to insert genetic sequences, base editing erases a point mutation and replaces with a new letter.
• The FDA has given the IND nod to their lead base-editing candidate, BEAM-101, as an autologous hematopoietic cell therapy to address sickle cell disease or beta-thalassemia.
• BEAM has an attractive financial position moving forward and has tripled its liquidity from 20Q3, with cash on hand at $933.4M with a meager $54.6M R&D cost for 21Q3.

For further details see: